scholarly journals Evaluation of potential serum biomarkers of hepatic fibrosis and necroinflammatory activity in dogs with liver disease

2018 ◽  
Vol 32 (3) ◽  
pp. 1009-1018 ◽  
Author(s):  
Chantel Raghu ◽  
Joanne Ekena ◽  
John M. Cullen ◽  
Craig B. Webb ◽  
Lauren A. Trepanier
Keyword(s):  
Liver Disease ◽  
Hepatic Fibrosis ◽  
Serum Biomarkers ◽  
Necroinflammatory Activity

Healing gone wrong: convergence of hemostatic pathways and liver fibrosis?

2020 ◽  
Vol 134 (16) ◽  
pp. 2189-2201
Author(s):  
Jessica P.E. Davis ◽  
Stephen H. Caldwell
Keyword(s):  
Wound Healing ◽  
Liver Disease ◽  
Hepatic Fibrosis ◽  
Cell Activation ◽  
Stellate Cell ◽  
Factor Xa ◽  
Clinical Trial Data ◽  
Chronic Liver ◽  
Healing Response ◽  
Wound Healing Response

Abstract Fibrosis results from a disordered wound healing response within the liver with activated hepatic stellate cells laying down dense, collagen-rich extracellular matrix that eventually restricts liver hepatic synthetic function and causes increased sinusoidal resistance. The end result of progressive fibrosis, cirrhosis, is associated with significant morbidity and mortality as well as tremendous economic burden. Fibrosis can be conceptualized as an aberrant wound healing response analogous to a chronic ankle sprain that is driven by chronic liver injury commonly over decades. Two unique aspects of hepatic fibrosis – the chronic nature of insult required and the liver’s unique ability to regenerate – give an opportunity for pharmacologic intervention to stop or slow the pace of fibrosis in patients early in the course of their liver disease. Two potential biologic mechanisms link together hemostasis and fibrosis: focal parenchymal extinction and direct stellate cell activation by thrombin and Factor Xa. Available translational research further supports the role of thrombosis in fibrosis. In this review, we will summarize what is known about the convergence of hemostatic changes and hepatic fibrosis in chronic liver disease and present current preclinical and clinical data exploring the relationship between the two. We will also present clinical trial data that underscores the potential use of anticoagulant therapy as an antifibrotic factor in liver disease.

Combining hepatic surface nodularity and serum tests better predicts hepatic fibrosis stages in chronic liver disease

2021 ◽  
Author(s):  
Hyo Jung Cho ◽  
Jaewon Choi ◽  
Bohyun Kim ◽  
JeongGil Ko ◽  
Joon-Il Choi ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Hepatic Fibrosis ◽  
Chronic Liver

Sa1055 Use of Insulin and Sulfonylurea Is Associated With Hepatic Fibrosis in Diabetic Patients With Non-Alcoholic Fatty Liver Disease

2014 ◽  
Vol 146 (5) ◽  
pp. S-948
Author(s):  
George Boon-Bee Goh ◽  
Jaividhya Dasarathy ◽  
Mangesh R. Pagadala ◽  
Aynur Unalp ◽  
Carol Hawkins ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Hepatic Fibrosis ◽  
Fatty Liver Disease ◽  
Diabetic Patients ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document